MK0928 Study in Adult Patients With Primary Insomnia (0928-040)(COMPLETED)
Phase 2
Completed
- Conditions
- Primary Insomnia
- Registration Number
- NCT00266344
- Lead Sponsor
- H. Lundbeck A/S
- Brief Summary
A study to evaluate the efficacy, safety and tolerability of MK-0928 in Primary Insomnia.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 520
Inclusion Criteria
- Patients with a diagnosis of primary insomnia
Exclusion Criteria
- Patients with an active psychiatric disorder other than primary insomnia
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- PARALLEL
- Primary Outcome Measures
Name Time Method Patient-reported total sleep time.
- Secondary Outcome Measures
Name Time Method Patient-reported time to sleep onset, number of awakenings, wake time after sleep onset and premature awakening.
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What are the molecular mechanisms of MK-0928 in treating primary insomnia?
How does MK-0928 compare to standard-of-care hypnotics in phase IIb trials for primary insomnia?
Are there specific biomarkers associated with response to MK-0928 in primary insomnia patients?
What adverse events were reported in the MK-0928 phase IIb trial for primary insomnia and how were they managed?
What other compounds or drug classes are being investigated for primary insomnia alongside MK-0928?